The CLL‐relevant genes that were up‐/downregulated by proximal SEs are depicted in Fig 4E and F. The list includes the T‐cell receptor alpha locus on chromosome 14 (TRA locus), the immune checkpoint receptor CTLA4, FMOD as a CLL tumor‐associated antigen allowing for expansion of specific CD8+ autologous T lymphocytes (Mayr et al, 2005), and BCL2, a highly successful therapeutic target (Kipps et al, 2017). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.